×
About 2,803 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  1,006 results

Arsenic compounds induce apoptosis by activating the MAPK and caspase pathways in FaDu ...
https://doi.org/10.3892/ijo.2022.5308
International Journal of Oncology; Wu SZ, Lan YY et. al.

Jan 15th, 2022 - For a number of years, oral cancer has remained in the top ten most common types of cancer, with an incidence rate that is steadily increasing. In total, ~75% oral cancer cases are associated with lifestyle factors, including uncontrolled alcohol ...

Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute ...
https://doi.org/10.1016/j.thromres.2021.12.020
Thrombosis Research; Xiao M, Zhou P et. al.

Jan 9th, 2022 - Acute promyelocytic leukemia (APL) is often accompanied by potentially fatal coagulopathy, especially in high-risk APL. Bleeding, particularly severe bleeding is the leading cause of early death (ED). Meanwhile, thrombosis, the other major coagulo...

'FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leu...
https://doi.org/10.1016/j.clml.2021.12.007
Clinical Lymphoma, Myeloma & Leukemia; Deka RR, Naseem S et. al.

Jan 7th, 2022 - NPM1 and FLT3-ITD are frequently mutated genes in acute myeloid leukemia. We studied clinico-hematological profile and survival outcome of adult acute promyelocytic leukemia (APL) patients harboring these mutations. De novo APL cases (> 12 years),...

Acute promyelocytic leukemia with Chediak-Higashi like giant granules.
https://doi.org/10.1182/blood.2021013975
Blood Zhang YH, Han X

Jan 7th, 2022 - Acute promyelocytic leukemia with Chediak-Higashi like giant granules.|2022|Zhang YH,Han X,|

Outcome and complications of pediatric acute promyelocytic leukemia in Bangladesh.
https://doi.org/10.1080/08880018.2021.2002486
Pediatric Hematology and Oncology; Khan ER, Islam A et. al.

Jan 6th, 2022 - Pediatric acute promyelocytic leukemia (APL) is one of the most curable subtypes of acute myeloid leukemia of childhood. But it may have many early complications, especially in developing countries. This study aims to describe the outcome and comp...

see more →

Guidelines  2 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  26 results

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03751917

Jan 4th, 2022 - Considering the clear therapeutic advantage associated with ATRA+ATO combination therapy and the more favorable and overall manageable safety profile compared to ATRA+chemotherapy, the benefits of the combination in the first-line indication do ap...

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT04996030

Nov 12th, 2021 - This study includes 3 parts: during one part, enrolled participants will receive a single dose of IV ATO, and a week later a single dose of SY-2101 either in the fed or fasted condition, and a week after that, a single dose of SY-2101 in the fed o...

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02200978

Sep 23rd, 2021 - OBJECTIVES: Determine the safety and efficacy of "ATO/RIF + ATRA + less intensive chemotherapy" protocol in children with acute promyelocytic leukemia (APL). Compare the safety,efficacy and treatment cost of "RIF + ATRA + less intensive chemother...

Selinexor (KPT-330) in Older Patients With Relapsed AML
https://clinicaltrials.gov/ct2/show/NCT02088541

Oct 8th, 2020 - This is a randomized, multicenter, open-label phase 2 study of the SINE compound, selinexor given orally versus restricted investigator choice (i.e., one of three potential salvage therapies). Participants who have never been transplant eligible, ...

Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
https://clinicaltrials.gov/ct2/show/NCT04489706

Jul 28th, 2020 - The P53 mutation plays an important role in the development of ovarian cancer and endometrial cancer, which has been found to occur in more than 95% of high grade serous ovarian cancers, 25% of the endometrial cancer, with serous endometrial cance...

see more →

News  74 results

'Shocking' Lack of Lifesaving Leukemia Drug at US Hospitals
https://www.medscape.com/viewarticle/964213

Dec 6th, 2021 - A drug crucial for the emergency management of acute promyelocytic leukemia (APL) simply isn't stocked by many US hospitals, according to a recent report in the Journal of the National Comprehensive Cancer Network. The drug — all-trans retinoic ac...

Quizartinib/Chemo Shows Superior OS Benefit Over Chemo Alone in Newly Diagnosed FLT3-ITD+ AML
https://www.onclive.com/view/quizartinib-chemo-shows-superior-os-benefit-over-chemo-alone-in-newly-diagnosed-flt3-itd-aml

Nov 19th, 2021 - The addition of quizartinib to standard induction and consolidation chemotherapy followed by quizartinib monotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) vs standard chemotherapy al...

'Remarkable' Results in Pediatric Acute Promyelocytic Leukemia
https://www.medscape.com/viewarticle/962943

Nov 15th, 2021 - "Remarkable" results with a novel treatment regimen in pediatric acute promyelocytic leukemia (APL) have been reported by researchers at the National Cancer Institute (NCI). Two-year event free survival (EFS) with the regimen was 98% and overall s...

Bringing Epigenetic Therapies From Bench to Bedside
https://www.onclive.com/view/bringing-epigenetic-therapies-from-bench-to-bedside

Oct 6th, 2021 - Ronan T. Swords, MD, PhD Pap Corps Endowed Professor in Leukemia Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Although there have been advances in therapeutics and supportive care, the...

How Close Is Close Enough?
https://www.onclive.com/view/how-close-is-close-enough

Oct 6th, 2021 - Andrew L. Pecora, MD Editor-in-Chief Oncology & Biotech News Chief Innovations Officer, Professor, and Vice President of Cancer Services John Theurer Cancer Center at Hackensack University Medical Center Imagine that an on...

see more →

Patient Education  1 results see all →